Clinical Trial Results:
Estudio en fase 1/2, abierto, adaptativo, aleatorio de doxorrubicina liposómica con o sin M200 (volociximab) para el tratamiento de pacientes con cáncer de ovario epitelial avanzado o cáncer peritoneal primario que han recaído después de una terapia previa con una quimioterapia basada en platinos / taxanos.
A Phase 1/2, Open-Label, Adaptive, Randomized Study of Liposomal Doxorubicin With or Without M200 (Volociximab) for the Treatment of Subjects With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer That Have Relapsed After Prior Therapy With a Platinum/Taxane-Based Chemotherapy
Summary
|
|
EudraCT number |
2007-000509-31 |
Trial protocol |
ES BE SE IT |
Global completion date |
20 Oct 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 Oct 2016
|
First version publication date |
01 Oct 2016
|
Other versions |
|
Summary report(s) |
Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.